Related Experiment Video
Updated: Feb 2, 2026
06:51
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
30.4K
[Establish a predictive modeling under antiviral therapy for hepatitis B e antigen seroconversion in chronic
1Department of Critical Liver Disease, Tianjin Second People's Hospital, Tianjin 300192, China.
Summary
Hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B patients is predicted by family history, fatty liver, HBV-DNA levels, and HBeAg. This finding aids in predicting treatment outcomes for HBeAg-positive individuals.
Area of Science:
- Hepatology
- Virology
- Predictive Modeling
Background:
- Chronic hepatitis B (CHB) is a significant global health concern.
- Hepatitis B e antigen (HBeAg) seroconversion is a key treatment endpoint in CHB.
- Predicting HBeAg seroconversion aids in tailoring antiviral therapy.
Purpose of the Study:
- To identify predictive factors for HBeAg seroconversion in HBeAg-positive CHB patients undergoing antiviral therapy.
- To develop a predictive model for HBeAg seroconversion at 144 weeks.
Main Methods:
- A cohort of 198 HBeAg-positive CHB patients was studied.
- Predictor variables included fatty liver, family history, HBeAg, HBsAg, HBV-DNA levels, and others.
- Logistic regression and ROC curve analysis were used to identify independent predictors and build a model.
Main Results:
- The HBeAg seroconversion rate was 36.87% at 144 weeks.
- Independent predictors identified were family history of hepatitis B, fatty liver, HBV-DNA levels, and HBeAg levels.
- A predictive model demonstrated good accuracy with an AUC of 0.875.
Conclusions:
- Family history of hepatitis B, fatty liver, HBV-DNA levels, and HBeAg are significant independent predictors of HBeAg seroconversion.
- The developed predictive model can assist in anticipating treatment responses in CHB patients.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:21Hepatic Portal System
5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
01:16Hepatic Drug Excretion: Influencing Factors
583
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
583
01:14Hepatic Drug Clearance: Role of Transporters
312
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
312
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
301
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
301